Radient Technologies Inc. Provides Update on Filing of First Quarter Financial Statements and Executive Compensation Disclosure

EDMONTON, Alberta, Sept. 28, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), announces that the Company will be relying on the temporary 45 day extension to the filing deadline of its financial statements and management’s discussion and analysis (“MD&A”) for the quarter […] Lire la suite »

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020

GAITHERSBURG, Md., Sept. 28, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The […] Lire la suite »

XBiotech entwickelt Kombination von True-Human-Antikörpern als Behandlungskanditaten für Influenza-COVID-19-Ko-Infektionen

AUSTIN, Texas (USA), Sept. 22, 2020 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) hat heute bekanntgegeben, dass das Unternehmen einen neuen bahnbrechenden Therapiekandidaten mit der Bezeichnung FLUVID™ zur Behandlung von Krankheiten entwickelt, die durch kombinierte Infektionen mit Influenza und COVID-19 verursacht werden. Mit der weltweiten Verbreitung des neuartigen COVID-19-Virus besteht […] Lire la suite »

XBiotech développe une combinaison d’anticorps True Human en tant que candidat-traitement pour la co-infection grippe/COVID-19

AUSTIN, Texas, 22 sept. 2020 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui le développement d’un nouveau candidat-traitement révolutionnaire appelé FLUVID™ pour le traitement des maladies causées par une combinaison d’infections par la grippe et par le COVID-19. Avec la propagation mondiale du nouveau virus COVID-19, il y […] Lire la suite »

Tiziana Life Sciences plc: Publication of Research Note

LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company“), is pleased to note the publication of a new analyst research note from H C Wainwright & Co which is available on the Company’s website at https://ir.tizianalifesciences.com/static-files/0bae55ef-6589-43f2-a4bd-65be16b3dce1 […] Lire la suite »

Radient Conducts Strategic Review of Operations and Announces Management Changes

EDMONTON, Alberta, Sept. 18, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX-V:RTI; OTCQX:RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, announces its Board of Directors (the “Board”) is conducting a strategic review of the Company’s operations targeting a path to positive cash flow by […] Lire la suite »

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

SHANGHAI, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug designation to Toripalimab for the treatment […] Lire la suite »

Precision BioSciences und Servier erweitern ihre Zusammenarbeit in der CAR-T-Entwicklung im Bereich Onkologie mit vier neuen Programmen, die auf hämatologische und solide Tumore abzielen

DURHAM, N.C. und PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), ein Biotechnologieunternehmen im Bereich der klinischen Forschung, das in Zusammenarbeit mit Servier, einem internationalen Pharmaunternehmen, allogene CAR-T- und In-vivo-Gentherapien mit seiner Genom-Editierplattform ARCUS® entwickelt, gab heute bekannt, dass die Unternehmen neben CD19 zwei weitere hämatologische Krebsziele […] Lire la suite »

Precision BioSciences et Servier étendent leur collaboration en matière de développement en oncologie concernant un traitement à base de cellules CAR T avec quatre nouveaux programmes ciblant les tumeurs hématologiques et solides

DURHAM, Caroline du Nord, et PARIS, 17 sept. 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq : DTIL), une société biotechnologique en phase clinique développant des traitements par correction génique in vivo et à base de cellules CAR T allogéniques avec sa plateforme d’édition de génomes ARCUS®, en collaboration avec Servier, […] Lire la suite »

Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

DURHAM, N.C. and PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, in collaboration with Servier, an independent global pharmaceutical company, today announced the companies have added […] Lire la suite »

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19 NEW YORK and LONDON, Sept. 17, 2020 (GLOBE NEWSWIRE) —  Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, […] Lire la suite »

Knopp Biosciences schließt Rekrutierung für Phase-II-Studie zu oral verabreichtem Dexpramipexol bei eosinophilem Asthma ab

PITTSBURGH, Sept. 16, 2020 (GLOBE NEWSWIRE) — Knopp Biosciences LLC gab heute bekannt, dass das Unternehmen die Rekrutierung für eine Studie der Phase II zum oral verabreichten niedermolekularen Wirkstoffkandidaten Dexpramipexol für die Behandlung von Patienten mit mäßigem bis schwerem eosinophilen Asthma abgeschlossen hat. Bei der 12-wöchigen multizentrischen Studie der Phase II […] Lire la suite »

Knopp Biosciences achève son recrutement dans l’essai de Phase 2 évaluant le dexpramipexole par voie orale dans l’asthme éosinophilique

PITTSBURGH, 16 sept. 2020 (GLOBE NEWSWIRE) — Knopp Biosciences LLC a annoncé aujourd’hui la fin du recrutement dans un essai de Phase 2 évaluant le dexpramipexole par voie orale à petites molécules chez des patients atteints d’asthme éosinophilique modéré à sévère. L’essai multicentrique de Phase 2 est une étude randomisée, en double […] Lire la suite »

Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration for Four Small Molecule Cancer Drug Candidates

SHANGHAI, China, Sept. 16, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that it has recently entered into a global development, manufacturing and commercialization collaboration with Wigen Biomedicine, a biomedical high-tech […] Lire la suite »

Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually

Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021 Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in 2021 Agreement expands Novavax partnership with world’s largest vaccine developer to increase global delivery of NVX-CoV2373 GAITHERSBURG, Md., Sept. 15, […] Lire la suite »

Radient Technologies Inc. Reports Financial Results for The Fourth Quarter and Fiscal Year 2020

Fiscal 2020 Revenues of $18.4 MillionAdvances White Label Strategy and Manufacturing Capabilities EDMONTON, Alberta, Sept. 14, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, today announced its fiscal results for the quarter and […] Lire la suite »

Evelo Biosciences Appoints Julie Carretero as Chief People Officer

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of Julie Carretero as Chief People Officer. In her new role, Ms. Carretero will assume leadership responsibilities for people […] Lire la suite »

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY® (diroximel fumarate) Real-world findings evaluate quality of life benefits associated with TYSABRI® (natalizumab) when compared to Ocrevus®(ocrelizumab) Additional real-world findings report positive benefits of PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a) in older […] Lire la suite »

Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

SHANGHAI, China, Sept. 10, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the US Food and Drug Administration (FDA) has recently granted Breakthrough Therapy designation (BTD) to Toripalimab for the […] Lire la suite »

Novavax to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373. Conference details are as follows: […] Lire la suite »